KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Invested Capital (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Invested Capital for 10 consecutive years, with 0.15% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital fell 8.0% to 0.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.15% through Dec 2025, down 8.0% year-over-year, with the annual reading at 0.16% for FY2025, 10.0% down from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.15% at Halozyme Therapeutics, down from 0.31% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.46% in Q3 2021, with the low at 0.12% in Q1 2023.
  • Average Return on Invested Capital over 5 years is 0.25%, with a median of 0.22% recorded in 2024.
  • The sharpest move saw Return on Invested Capital skyrocketed 55bps in 2021, then tumbled -32bps in 2023.
  • Over 5 years, Return on Invested Capital stood at 0.44% in 2021, then plummeted by -70bps to 0.13% in 2022, then increased by 24bps to 0.16% in 2023, then surged by 40bps to 0.23% in 2024, then plummeted by -34bps to 0.15% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.15%, 0.31%, and 0.29% for Q4 2025, Q3 2025, and Q2 2025 respectively.